1. 92P Development and characterization of induced pluripotent stem cells derived from calpainopathy patients, carrying the CAPN3 c.1746-20C>G variant.
- Author
-
Inashkina, I., Goluba, K., Tvoronoviča, A., Parfejevs, V., Lāce, B., and Riekstiņa, U.
- Subjects
- *
INDUCED pluripotent stem cells , *INFORMED consent (Medical law) , *LIMB-girdle muscular dystrophy , *GENETIC engineering , *GENETIC variation - Abstract
Calpainopathy is a progressive autosomal recessive calpain-3-related limb-girdle muscular dystrophy type R1 (LGMDR1) caused by variants in CAPN3 gene. The intronic variant NM_000070.3:c.1746-20C>G in CAPN3 gene has a frequency of >1%, and there are conflicting interpretations on its pathogenicity. We have shown that c.1746-20C>G, which is common in Latvia (MAF 0.237) affects splicing of the CAPN3 gene, therefore suggested reclassifying it as hypomorphic. Our new aim is to establish calpainopathy patient-derived induced pluripotent stem cells (iPSCs) and create a disease model that recapitulates unique CAPN3 variants. Patients provided informed consent, and experimental procedures were approved by the Central Medical Ethics Committee of Latvia. Fibroblasts were isolated from a skin biopsy by microdissection technique. 2nd passage fibroblasts were transduced with CytoTuneTM-iPS 2.0 Sendai reprogramming kit. Three iPSC clones from each patient were established showing PSC-like morphology with densely packed and round colonies with smooth edges. iPSC clones showed expression of Oct-4, Nanog, Sox2, SSEA-4, and Tra-1-60 markers. The directed trilineage differentiation confirmed the pluripotency of the iPSC clones. The expression of ectoderm, mesoderm, and endoderm markers was analysed by immunofluorescence analysis and TaqMan hPSC scorecard assay. The genotype stability of clones was assessed by karyotyping and CMA assay, and identity was confirmed with STR profile analysis. Next, skeletal myoblast differentiation will be initiated to establish a model system for screening of novel calpainopathy therapies. LGMDR1 patient-derived iPSCs will be registered in hPSCreg registry and serve as a model to study the molecular mechanisms of the disease and facilitate the discovery of personalized therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF